

Nocturia - Pipeline Insight, 2021

<https://marketpublishers.com/r/N93F8C481ADEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N93F8C481ADEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Nocturia – Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nocturia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Nocturia Understanding

Nocturia: Overview

Nocturia is a condition that causes you to wake up during the night to urinate. This can be thought of as nocturnal urinary frequency — having to urinate more often at night. This condition becomes more common as people age and occurs in both men and women. Nocturia can be caused by: Polyuria: when a body makes too much urine in a 24-hour period, Nocturnal polyuria: when a body makes too much urine during the night, Bladder storage problems: when a bladder doesn't store or release urine well. Mixed nocturia: when more than one of these problems are happening. Nocturia can have significant health consequences. It may be connected to serious underlying problems, and nighttime bathroom trips can both disrupt sleep and create additional health concerns. Anticholinergic medications (these can reduce symptoms of an overactive bladder), Bumetanide (Bumex®), Furosemide (Lasix®) (diuretics that assist in

regulating urine production), Desmopressin (DDAVP®) (helps the kidneys produce less urine) might be helpful in treating the condition.

'Nocturia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nocturia pipeline landscape is provided which includes the disease overview and Nocturia treatment guidelines. The assessment part of the report embraces, in depth Nocturia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nocturia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nocturia R&D. The therapies under development are focused on novel approaches to treat/improve Nocturia.

Nocturia Emerging Drugs Chapters

This segment of the Nocturia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nocturia Emerging Drugs

Fedovapagon: Vantia Therapeutics

Vantia Therapeutics is developing fedovapagon, an orally administered, small-molecule vasopressin V2 agonist, for the treatment of Nocturia. Vantia Therapeutics reported positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign prostatic hyperplasia.

FE 201836: Ferring Pharmaceuticals

An oral solution of FE 201836 for treatment of nocturia is being developed by Ferring Pharmaceuticals. Clinical developments are underway in U.S for treatment of Nocturia.

Further product details are provided in the report

Nocturia: Therapeutic Assessment

This segment of the report provides insights about the different Nocturia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nocturia

There are approx. 5+ key companies which are developing the therapies for Nocturia. The companies which have their Nocturia drug candidates in the most advanced stage, i.e. Phase II/III include, Vanita Therapeutics.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nocturia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nocturia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nocturia therapeutic drugs key players

involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nocturia drugs.

Nocturia Report Insights

Nocturia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Nocturia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Nocturia drugs?

How many Nocturia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nocturia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nocturia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nocturia and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Nocturia: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Nocturia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Nocturia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Nocturia Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase II/III)
 - Comparative Analysis
- Fedovapagon: Vantia Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- FE 201836: Ferring Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report

Early stage products (Phase I)

Comparative Analysis

USRP 003: Kao Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Nocturia Key Companies

Nocturia Key Products

Nocturia- Unmet Needs

Nocturia- Market Drivers and Barriers

Nocturia- Future Perspectives and Conclusion

Nocturia Analyst Views

Nocturia Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Nocturia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Nocturia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Nocturia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/N93F8C481ADEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N93F8C481ADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970